We interview Dr. Steven Waggoner on the NRG Oncology Ancillary Projects Committee (APC) and the conduct of ancillary projects.

We interview Dr. Erin Gillespie, PI of the NRG-CC014 "PREEMPT" study comparing radiation therapy to usual therapy for patients with high-risk bone metastases that are not causing pain.

We interview NRG Deputy Director of Membership and Research Integrity, Dr. David Miller, on the ins-and-outs of NRG Membership and the NRG Membership Committee.

We interview Dr. Jeff Bradley, the now Immediate Past Chair of the NRG Lung Cancer Committee regarding the past, present, and future of lung cancer in NRG as well as the importance of mentorship for our future research.

Dr. Ted Hong discusses the NRG-GI003 study comparing proton versus photons for hepatocellular carcinoma.

NRG Oncology Podcast Co-hosts sit with Dr. Edward Tanner, the Principal Investigator of the NRG-CC010 trial assessing the impact of sentinel lymph node mapping on patient-reported lower extremity limb dysfunction in endometrial cancer.

We discuss the results of NRG-NSABP B-51/RTOG 1304 in breast cancer, reported today in the New England Journal of Medicine.

Our co-hosts discuss triple-negative breast cancer in light of the recently presented results at the 2025 ASCO Annual Meeting. We interview Dr. Vicente Valero, the NRG-BR003 PI, and Dr. Julie Gralow, the Chief Medical Officer of ASCO about these findings and current research in breast cancer.

The NRG Oncology Podcast Co-hosts sit with NRG Oncology Patient Advocate, Tambre Leighn, to discuss what our patient advocates do in the process of our clinical trials from concept to reporting results. Tambre dives into the benefits of a great patient-physician relationship in building stronger trials as well as the need to tailor our trials around our patients' needs. Tambre also talks about the specific training advocates are encouraged to go through to help learn more about the clinical research process.

NRG Oncology Podcast co-hosts talk with Dr. Vinai Gondi, the Principal Investigator of the NRG-CC009 phase III clinical study assessing stereotactic radiosurgery (SRS) versus hippocampal-avoidant whole brain radiotherapy (HA-WBRT) for patients who have brain metastases (or cancer that has spread to the brain) from their small cell lung cancer (SCLC).